Click Here for 5% Off Your First Aladdin Purchase!
Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Vobarilizumab (anti-IL-6Ra) - Primary antibody, specific to IL6R, >95%, high purity, Human IgG1, Antibody of Interleukin-6 receptor

  • Azide Free
  • Carrier Free
  • ExactAb™
  • Low Endotoxin
  • Recombinant
  • Validated
  • ≥95%(SDS-PAGE&SEC)
  • Lot by Lot
Features and benefits
  • Short Overview:

    Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

  • Species reactivity(Reacts with): Cynomolgus monkey,Human
  • Isotype: Human IgG1
    Application:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
Item Number
Ab175700
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab175700-100μg
100μg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$79.90
Ab175700-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$399.90
Ab175700-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,279.90
Ab175700-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,079.90
Add to Wish List Compare
Bulk Order  DATASHEET

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series
Accession#:P08887 Gene ID:3570 IL6R Interleukin-6 receptor Antibody

Basic Description

Product NameVobarilizumab (anti-IL-6Ra) - Primary antibody, specific to IL6R, >95%, high purity, Human IgG1
SynonymsCD 126 antibody; CD126 antibody; CD126 antigen antibody; gp80 antibody; IL 6R 1 antibody; IL 6R alpha antibody; IL 6R antibody; IL-6 receptor alpha chain antibody; IL-6 receptor subunit alpha antibody; IL-6R 1 antibody; IL-6R subunit alpha antibody; IL-6R
Specifications & PurityExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
SpecificityIL6R
ConjugationUnconjugated
GradeAzide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action TypeINHIBITOR
Mechanism of actionAntibody of Interleukin-6 receptor
Product Description

Vobarilizumab (anti-IL-6Ra) is an anti-IL-6R monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab (anti-IL-6Ra) consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab (anti-IL-6Ra) can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis.

Product Properties

IsotypeHuman IgG1
Light Chain TypescFv
SDS-PAGE78.2 kDa
Purification MethodProtein A purified
Purity>95%
FormLiquid
ConcentrationLot by Lot
Storage TempStore at -80°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS1628814-88-9

Images

Vobarilizumab (anti-IL-6Ra) (Ab175700) - ELISA
Immobilized human IL-6R-ECD-chis at 2.0 μg/mL can Vobarilizumab (anti-IL-6Ra) (Ab175700) with the EC₅₀ of 13.89 ng/mL.



Vobarilizumab (anti-IL-6Ra) (Ab175700) - SEC
The purity of Vobarilizumab (anti-IL-6Ra) (Ab175700) is more than 95% verified by HPLC.

Vobarilizumab (anti-IL-6Ra) (Ab175700) - ELISA
Immobilized Recombinant Human IL-6R alpha Protein (rp181252) at 1.0 μg/mL can bind Vobarilizumab (anti-IL-6Ra) (Ab175700) with the EC50 of 67.99 ng/mL.

Associated Targets

IL6R Tclin Interleukin-6 receptor subunit alpha 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

IL6ST Tclin Interleukin-6 receptor subunit beta 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

3 results found

Lot NumberCertificate TypeDateItem
ZJ24F0404187Certificate of AnalysisApr 07, 2024 Ab175700
ZJ24F0404186Certificate of AnalysisApr 07, 2024 Ab175700
ZJ24F0404185Certificate of AnalysisApr 07, 2024 Ab175700

Related Documents

 SDS

 Specification Sheet

References

1. Tackey E, Lipsky PE, Illei GG.  (2004)  Rationale for interleukin-6 blockade in systemic lupus erythematosus..  Lupus,  13  (5): (339-43).  [PMID:15230289]
2. Kristiansen OP, Mandrup-Poulsen T.  (2005)  Interleukin-6 and diabetes: the good, the bad, or the indifferent?.  Diabetes,  54 Suppl 2  (3): (S114-24).  [PMID:16306329]
3. Hirohata S, Kikuchi H.  (2012)  Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Behçet's disease..  Intern Med,  51  (24): (3359-65).  [PMID:23257520]
4. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L et al..  (2015)  The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis..  Arthritis Res Ther,  17  (3): (135).  [PMID:25994180]
5. A-González N, Castrillo A.  (2011)  Liver X receptors as regulators of macrophage inflammatory and metabolic pathways..  Biochim Biophys Acta,  1812  (8): (982-94).  [PMID:21193033]
6. Varghese JN, Moritz RL, Lou MZ, Van Donkelaar A, Ji H, Ivancic N, Branson KM, Hall NE, Simpson RJ.  (2002)  Structure of the extracellular domains of the human interleukin-6 receptor alpha -chain..  Proc Natl Acad Sci USA,  99  (25): (15959-64).  [PMID:12461182]
7. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC.  (2003)  Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex..  Science,  300  (5628): (2101-4).  [PMID:12829785]
8. Kang S, Tanaka T, Narazaki M, Kishimoto T.  (2019)  Targeting Interleukin-6 Signaling in Clinic..  Immunity,  50  (4): (1007-1023).  [PMID:30995492]
9. Li H, Xiao H, Lin L, Jou D, Kumari V, Lin J, Li C..  (2014)  Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface..  J Med Chem,  57  (3): (632-641).  [PMID:24456369]
10. Schooltink, H H and 7 more authors..  (1991)  Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells..  The Biochemical journal,    (1):   [PMID:1872801]
11. Novick, D D, Engelmann, H H, Wallach, D D and Rubinstein, M M..  (1989)  Soluble cytokine receptors are present in normal human urine..  The Journal of experimental medicine,    (1):   [PMID:2529343]
12. Yamasaki, K K and 8 more authors..  (1988)  Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor..  Science (New York, N.Y.),    (12):   [PMID:3136546]
13. Horiuchi, S S and 8 more authors..  (1994)  Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism..  European journal of immunology,      [PMID:8056053]
14. Yawata, H H and 7 more authors..  (1993)  Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130..  The EMBO journal,      [PMID:8467812]
15. Cole, A R AR and 6 more authors..  (1999)  Disulfide bond structure and N-glycosylation sites of the extracellular domain of the human interleukin-6 receptor..  The Journal of biological chemistry,    (12):   [PMID:10066782]
16. Martens, A S AS, Bode, J G JG, Heinrich, P C PC and Graeve, L L..  (2000)  The cytoplasmic domain of the interleukin-6 receptor gp80 mediates its basolateral sorting in polarized madin-darby canine kidney cells..  Journal of cell science,      [PMID:11017875]
17. Nakahara, Hideko H and 6 more authors..  (2003)  Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis..  Arthritis and rheumatism,      [PMID:12794819]
18. Buk, Deborah M DM, Renner, Olga O and Graeve, Lutz L..  (2005)  Increased association with detergent-resistant membranes/lipid rafts of apically targeted mutants of the interleukin-6 receptor gp80..  European journal of cell biology,      [PMID:16270750]
19. Smolen, Josef S JS and Maini, Ravinder N RN..  (2006)  Interleukin-6: a new therapeutic target..  Arthritis research & therapy,      [PMID:16899109]
20. Reich, David D and 23 more authors..  (2007)  Admixture mapping of an allele affecting interleukin 6 soluble receptor and interleukin 6 levels..  American journal of human genetics,      [PMID:17357077]
21. Betts, Brian C BC, St Angelo, Erin T ET, Kennedy, Michael M and Young, James W JW..  (2011)  Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses..  Blood,    (10):   [PMID:21940820]
22. Huizinga, Tom W J TW and 9 more authors..  (2014)  Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial..  Annals of the rheumatic diseases,      [PMID:24297381]
23. and Lin, Phoebe P..  (2015)  Targeting interleukin-6 for noninfectious uveitis..  Clinical ophthalmology (Auckland, N.Z.),      [PMID:26392750]
24. Lokau, Juliane J and 13 more authors..  (2016)  Proteolytic Cleavage Governs Interleukin-11 Trans-signaling..  Cell reports,    (23):   [PMID:26876177]
25. June, Rayford R RR and Olsen, Nancy J NJ..  (2016)  Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis..  Expert opinion on biological therapy,      [PMID:27464017]
26. Riethmueller, Steffen S and 23 more authors..  (2017)  Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation..  PLoS biology,      [PMID:28060820]
27. Smolen, Josef S JS and 48 more authors..  (2017)  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update..  Annals of the rheumatic diseases,      [PMID:28264816]
28. Larsen, Jakob Vejby JV and Petersen, Claus Munck CM..  (2017)  SorLA in Interleukin-6 Signaling and Turnover..  Molecular and cellular biology,    (1):   [PMID:28265003]
29. Kampan, Nirmala Chandralega NC and 5 more authors..  (2018)  Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities..  Current medicinal chemistry,      [PMID:28707587]
30. Spencer, Sarah and 37 more authors..  (2019)  Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses..  The Journal of experimental medicine,    (2):   [PMID:31235509]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.